Catherine Dive‐Pouletty

Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

Patrick Vermersch, Jeremy Hobart, Catherine Dive‐Pouletty et al. · Multiple Sclerosis Journal · 2016 · 56 citations · Full text

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use

Paul O’Connor, Fred Lublin, Jerry S. Wolinsky et al. · Journal of Neurology · 2013 · 40 citations · Full text

Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life – A post hoc analysis of the TEMSO and TOWER studies

Mathias Mäurer, Mark Freedman, Ludwig Kappos et al. · Multiple Sclerosis and Related Disorders · 2016 · 39 citations · Full text

Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis

Mark S. Freedman, Xavier Montalbán, Aaron E. Miller et al. · Multiple Sclerosis and Related Disorders · 2016 · 32 citations · Full text

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study

Aaron Miller, Richard Macdonell, Mark Freedman et al. · Journal of Neurology · 2014 · 24 citations · Full text